Comparing ComfiJ and Conventional Double-J Ureteral Stents for Reducing Symptoms After Surgery for Urinary Stones in Adults

What this Trial Is About

Researchers are investigating ureteral stent-related symptoms in adults who need temporary stenting after unilateral ureteroscopy or retrograde intrarenal surgery for urinary stones. The study compares a newer ComfiJ ureteral stent with a conventional double-J ureteral stent to understand which stent causes fewer urinary symptoms and related issues. The trial is randomized and multicenter, focusing on patient comfort and quality of life after surgery. Participants will be randomly assigned during surgery to receive either a ComfiJ or conventional double-J ureteral stent if short-term postoperative stenting is needed. The stents are planned to remain in place for about 14 days before removal. The study uses a double-blind design where patients and outcome assessors do not know which stent was used, while surgeons are aware during insertion. Throughout the study, participants will complete the Arabic Ureteral Stent Symptom Questionnaire to assess urinary symptoms, along with pain scores and records of analgesic use, emergency visits, and complications. Researchers will also monitor stent migration, ease of insertion and removal, and patient satisfaction. The main outcome is the urinary symptoms score on day 14 before stent removal. Follow-up assessments occur up to postoperative day 14, and the study is scheduled to end in May 2027.

ComfiJ Versus Conventional Double-J Stent for Ureteral Stent Symptoms